Rudnick PA, Clauser KR, Kilpatrick LE, et al. Performance metrics for liquid chromatography-tandem mass spectrometry systems in proteomics analyses. Mol Cell Proteomics. 2010;9(2):225-41. doi:10.1074/mcp.M900223-MCP200
Boulbes D, Chen CH, Shaikenov T, et al. Rictor phosphorylation on the Thr-1135 site does not require mammalian target of rapamycin complex 2. Mol Cancer Res. 2010;8(6):896-906. doi:10.1158/1541-7786.MCR-09-0409
Whiteaker JR, Zhao L, Abbatiello SE, et al. Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry. Mol Cell Proteomics. 2011;10(4):M110.005645. doi:10.1074/mcp.M110.005645
Gerszten RE, Asnani A, Carr SA. Status and prospects for discovery and verification of new biomarkers of cardiovascular disease by proteomics. Circ Res. 2011;109(4):463-74. doi:10.1161/CIRCRESAHA.110.225003
Yu M, Romer KA, Nieland TJF, et al. Exoplasmic cysteine Cys384 of the HDL receptor SR-BI is critical for its sensitivity to a small-molecule inhibitor and normal lipid transport activity. Proc Natl Acad Sci U S A. 2011;108(30):12243-8. doi:10.1073/pnas.1109078108
Zhao L, Whiteaker JR, Pope ME, et al. Quantification of proteins using peptide immunoaffinity enrichment coupled with mass spectrometry. J Vis Exp. 2011;(53). doi:10.3791/2812
Kemp MM, Weïwer M, Koehler AN. Unbiased binding assays for discovering small-molecule probes and drugs. Bioorg Med Chem. 2012;20(6):1979-89. doi:10.1016/j.bmc.2011.11.071
George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008;455(7215):975-8. doi:10.1038/nature07397
Dutt A, Salvesen HB, Chen TH, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A. 2008;105(25):8713-7. doi:10.1073/pnas.0803379105
Lee JC, Vivanco I, Beroukhim R, et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006;3(12):e485. doi:10.1371/journal.pmed.0030485